Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).
Floridia M, Bucciardini R, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Amici R, Andreotti M, Ricciardulli D, Tomino C, Vella S; ISS-IP1 study group. Floridia M, et al. Among authors: tomino c. HIV Med. 2004 Jan;5(1):1-10. doi: 10.1111/j.1468-1293.2004.00177.x. HIV Med. 2004. PMID: 14731162 Free article. Clinical Trial.
Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).
Floridia M, Massella M, Bucciardini R, Perucci CA, Rossi L, Tomino C, Fragola V, Ricciardulli D, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Mirra M, Vella S. Floridia M, et al. Among authors: tomino c. HIV Clin Trials. 2000 Sep-Oct;1(2):9-16. doi: 10.1310/6ulm-xyb7-h4xp-bhfj. HIV Clin Trials. 2000. PMID: 11590493 Clinical Trial.
A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
Floridia M, Vella S, Seeber AC, Tomino C, Fragola V, Weimer LE, Ricciardulli D, Milazzo F, Gritti FM, Mazzotta F, Ranieri S, Chiodo F, Moroni M, Cargnel A, Bassetti D, Giannini V, Cremoni L, Concia E, Sinicco A, Carosi G, Alberici F, Dianzani F. Floridia M, et al. Among authors: tomino c. J Infect Dis. 1997 Feb;175(2):255-64. doi: 10.1093/infdis/175.2.255. J Infect Dis. 1997. PMID: 9203645 Clinical Trial.
Inhibition of HECT E3 ligases as potential therapy for COVID-19.
Novelli G, Liu J, Biancolella M, Alonzi T, Novelli A, Patten JJ, Cocciadiferro D, Agolini E, Colona VL, Rizzacasa B, Giannini R, Bigio B, Goletti D, Capobianchi MR, Grelli S, Mann J, McKee TD, Cheng K, Amanat F, Krammer F, Guarracino A, Pepe G, Tomino C, Tandjaoui-Lambiotte Y, Uzunhan Y, Tubiana S, Ghosn J; COVID Human Genetic Effort; French COVID Cohort Study Group; CoV-Contact Cohort; Notarangelo LD, Su HC, Abel L, Cobat A, Elhanan G, Grzymski JJ, Latini A, Sidhu SS, Jain S, Davey RA, Casanova JL, Wei W, Pandolfi PP. Novelli G, et al. Among authors: tomino c. Cell Death Dis. 2021 Mar 24;12(4):310. doi: 10.1038/s41419-021-03513-1. Cell Death Dis. 2021. PMID: 33762578 Free PMC article.
A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.
Floridia M, Bucciardini R, Ricciardulli D, Fragola V, Pirillo MF, Weimer LE, Tomino C, Giannini G, Galluzzo CM, Andreotti M, Cargnel A, Alberici F, De Rienzo B, Leoncini F, Fiaccadori F, Francisci D, Grillone W, Ortona L, Piazza M, Scalzini A, Nigra E, Tumietto F, Vella S. Floridia M, et al. Among authors: tomino c. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):11-9. doi: 10.1097/00042560-199901010-00002. J Acquir Immune Defic Syndr Hum Retrovirol. 1999. PMID: 9928724 Clinical Trial.
79 results